Intraperitoneal hyperthermic perfusion (IPHP): Analysis of morbidity and toxicity

Intraperitoneal hyperthermic perfusion (IPHP) with a solution that contains CDDP (25 mg/m²/l) and MMC (3.3 mg/m²/l) was clinically introduced in the treatment of peritoneal carcinomatosis. Twenty-six patients underwent surgical treatment and IPHP. Peritoneal carcinomatosis was classified at laparotomy using the Japanese classification: P1 (n=3), P2 (n=5), P3 (n=15), unclassifiable (n=3). In this series of patients only the creatinine and amylase values were significant in biological toxicity evaluation. The surgical complication rate (2 duodenal fistulas) does not differ from the general extensive abdominal surgery.